Pharma China
Access to the biggest consumer market.
Pharma China Consulting was founded in 2017 in Germany, is a professional insider for license in/out business for China, USA, EU and all over the world with 150 years common experience.
As a Pharma/Biotech consulting company based in Munich Germany we are serving our clients in China, USA, EU to build trust and work together for a long term win-win.
Main Sector: Professional Services and Consulting
Subsector(s): Business development, Deal arrangment, Event organization, Market Research
Primary therapeutic area(s): Cardiovascular, Congenital malformations, deformations and chromosomal abnormalities, Digestive system, Diseases of the blood and blood-forming organs; immune disorders, Diseases of the ear, Diseases of the eye, Diseases of the nervous system, Endocrine, nutritional and metabolic diseases, External causes of morbidity and mortality, Mental and behavioural disorders
Partnering strategy / collaborations
We solve problems for our clients. Our strengths are communications across cultures and deep understanding of the need of our partners.
Client portfolio
Reneo Pharma (USA), Fidia (Italy), Neuraxpharma (Spain), Welding (Germany), Winhealth (Hong Kong), China Resource(China), Hemony (China), Hisun (China), Hasten Pharma (China), Auzone Biotech, Farmamondo (Switzerland), APR(Switzerland) ......
Another Milestone: License in China of AFT Pharmaceulicals
find out more at below link
https://investors.aftpharm.com/DownloadFile.axd?file=Announcements/NZX/20240930/428359.pdf
Consulting for Chinese Market
谢红女士
your right business partner
BRIDGE China and Europe
Pharma-China的服务:
药品消费结构与医药商业
2015年我国OTC市场规模超过2000亿元。预计到2016年,我国OTC市场规模将达到2250亿元,到2020年我国OTC市场规模将位居世界第一.
在药品市场增长空间方面,中国将是潜力最大的市场。随着中国开始向中高收入国家迈进以及人口老龄化的加快,人民生活需求和消费结构将发生重大变化,对医疗卫生服务和自我保健的需求将大幅度增加,药品市场增长潜力巨大。预计2019年,中国药品终端市场规模将达到40188亿元,其中零售药店市场规模将达6914亿元。
医药电子商务前景预测:2015年B2C交易额达到152.1亿元。至2020年,中国医药电子商务B2C市场规模将超过1000亿元。B2B, B2C 市场的发展对行业的营销渠道提出新的要求,新的规则,需要新的解决方案